Free tool
FAERS Monitor: Relistor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021964 or its brand name (Relistor, Methylnaltrexone Bromide). Reports on generic versions are filed under their own applications.
Reports
1,520
Serious
905
60% of reports
Hospitalization
347
Death reported
335
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death246
- drug ineffective208
- nausea118
- constipation113
- abdominal pain106
- pain84
- diarrhoea81
- vomiting77
- fatigue67
- headache58
- abdominal pain upper57
- off label use51
- dyspnoea44
- weight decreased44
- malaise43
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2008 | 10 |
| 2009 | 38 |
| 2010 | 44 |
| 2011 | 61 |
| 2012 | 25 |
| 2013 | 25 |
| 2014 | 40 |
| 2015 | 49 |
| 2016 | 144 |
| 2017 | 166 |
| 2018 | 137 |
| 2019 | 217 |
| 2020 | 148 |
| 2021 | 109 |
| 2022 | 71 |
| 2023 | 62 |
| 2024 | 59 |
| 2025 | 61 |
| 2026 | 53 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| constipationSignal | 113 | 7.2 | 6.0 | 600 |
| abdominal painSignal | 106 | 6.3 | 5.2 | 473 |
| deathSignal | 246 | 4.0 | 3.5 | 562 |
| abdominal pain upperSignal | 57 | 3.8 | 3.0 | 118 |
| vomitingSignal | 77 | 2.3 | 1.8 | 54 |
| drug ineffectiveSignal | 208 | 2.2 | 1.9 | 141 |
| weight decreasedSignal | 44 | 2.2 | 1.6 | 27 |
| nauseaSignal | 118 | 2.1 | 1.7 | 66 |
| pain | 84 | 1.9 | 1.5 | 35 |
| diarrhoea | 81 | 1.7 | 1.4 | 25 |
| malaise | 43 | 1.4 | 1.0 | 4 |
| headache | 58 | 1.3 | 1.0 | 3 |
| fatigue | 67 | 1.2 | 0.9 | 2 |
| dyspnoea | 44 | 1.1 | 0.8 | 0 |
| off label use | 51 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.